Display options
Cite
Orfanos CE, Goerz G. Orale psoriasis-Therapie mit einem neuen aromatischen Retinoid (Ro 10-9359). Eine multizentrische kontrollierte Studie an 291 Patienten in der Bundesrepublik. Vorläufige Mitteilung. [Oral psoriasis treatment with a new aromatic retinoid (Ro 10-9359): a multi-centre controlled study of 291 patients (preliminary results) (author's transl)]. Dtsch Med Wochenschr. 1978;103(5):195-9doi: 10.1055/s-0028-1104405.
Orfanos, C. E., & Goerz, G. (1978). Orale psoriasis-Therapie mit einem neuen aromatischen Retinoid (Ro 10-9359). Eine multizentrische kontrollierte Studie an 291 Patienten in der Bundesrepublik. Vorläufige Mitteilung. [Oral psoriasis treatment with a new aromatic retinoid (Ro 10-9359): a multi-centre controlled study of 291 patients (preliminary results) (author's transl)]. Deutsche medizinische Wochenschrift (1946), 103(5), 195-9. https://doi.org/10.1055/s-0028-1104405
Orfanos, C E, and Goerz, G. "Orale psoriasis-Therapie mit einem neuen aromatischen Retinoid (Ro 10-9359). Eine multizentrische kontrollierte Studie an 291 Patienten in der Bundesrepublik. Vorläufige Mitteilung." [Oral psoriasis treatment with a new aromatic retinoid (Ro 10-9359): a multi-centre controlled study of 291 patients (preliminary results) (author's transl)]. Deutsche medizinische Wochenschrift (1946) vol. 103,5 (1978): 195-9. doi: https://doi.org/10.1055/s-0028-1104405
Orfanos CE, Goerz G. Orale psoriasis-Therapie mit einem neuen aromatischen Retinoid (Ro 10-9359). Eine multizentrische kontrollierte Studie an 291 Patienten in der Bundesrepublik. Vorläufige Mitteilung. [Oral psoriasis treatment with a new aromatic retinoid (Ro 10-9359): a multi-centre controlled study of 291 patients (preliminary results) (author's transl)]. Dtsch Med Wochenschr. 1978 Feb 03;103(5):195-9. doi: 10.1055/s-0028-1104405. German. PMID: 631039.
Copy Download .nbib Format: NLM
Share it on
Full text links
Georg Thieme Verlag Stuttgart, New York

Dtsch Med Wochenschr. 1978 Feb 03;103(5):195-9. doi: 10.1055/s-0028-1104405.

[Oral psoriasis treatment with a new aromatic retinoid (Ro 10-9359): a multi-centre controlled study of 291 patients (preliminary results) (author's transl)].

Deutsche medizinische Wochenschrift (1946)

[Article in German]
C E Orfanos, G Goerz

PMID: 631039 DOI: 10.1055/s-0028-1104405

Abstract

In a multi-centre study 291 patients with psoriasis were treated with (a) oral doses of the recently developed retinoid Ro 10-9359, (b) classical local dithranol application, and (c) both. In a preliminary evaluation of 203 patients treated orally excellent or good results were obtained in 120 (61%), no response in 31 (15.8%). The initial dose was 1.0 mg/kg body-weight daily, i.e. 50-75 mg, which was then reduced to 25-50 mg daily. A clinical response was noted after 2-3 weeks. Particularly, severe erythrodermic and pustular forms of the disease responded surprisingly well to the drug so that cytostatic agents were avoided. Under long-term administration, however, relapses were still seen. Most side-effects were reasonably well tolerated. But in 14% of patients the drug had to be discontinued because of hair loss, paronychia or slight elevation of transaminases (up to 40 U/I). This new drug is thus a potent antipsoriatic agent: it is effective, easily controlled and causes only moderate side-effects.

Similar articles

Substances

MeSH terms

Publication Types

LinkOut - more resources